| NCT06663787 | Nagoya City University | Breast Cancer, Metastatic|HER2 &addition; Breast Cancer | 2024-04-01 | |
| NCT07193394 | Institut Curie|Pfizer|Eurofins|UNICANCER | Metastatic Breast Cancer ( HER2 Negative)|Unresectable Breast Cancer | 2026-01-31 | PHASE2 |
| NCT00095706 | Translational Oncology Research International|Genentech, Inc. | Breast Cancer | 2003-06 | PHASE1|PHASE2 |
| NCT01450696 | Hoffmann-La Roche | Gastric Cancer | 2011-12 | PHASE3 |
| NCT04170595 | Genor Biopharma Co., Ltd. | HER2-positive Breast Cancer | 2014-03-28 | PHASE1|PHASE2 |
| NCT03272477 | Palleos Healthcare GmbH|Roche Pharma AG|WSG WOMEN?S HEALTHCARE STUDY GROUP|Cankado GmbH | Breast Neoplasms | 2017-10-05 | PHASE2 |
| NCT00470704 | Nancy Lin, MD|GlaxoSmithKline|Novartis | Breast Cancer | 2007-05-14 | PHASE2 |
| NCT01503905 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer Nos Premenopausal | 2011-12 | NA |
| NCT02380131 | Hebei Medical University | HER-2 Positive Gastric Cancer|Liver Metastasis | 2013-02 | PHASE4 |
| NCT03013881 | United BioPharma|Tri-Service General Hospital | Breast Neoplasm | 2018-03-05 | PHASE1 |
| NCT05765357 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Breast Cancer|Metastatic Gastric Cancer | 2017-07-16 | PHASE1 |
| NCT00133796 | Mothaffar Rimawi|Genentech, Inc. | BREAST CANCER | 2001-10 | PHASE2 |
| NCT00724360 | Nantes University Hospital | Relapsed+Refractory Leukemia | 2006-11 | PHASE2 |
| NCT02149524 | Samsung Bioepis Co., Ltd. | HER2 Positive Early or Locally Advanced Breast Cancer | 2014-04 | PHASE3 |
| NCT00440622 | Hellenic Oncology Research Group|University Hospital of Crete | Breast Cancer | 2003-04 | PHASE3 |
| NCT07565324 | National Taiwan University Hospital|TTY Biopharm | HER-2 Positive Breast Cancer | 2026-04-30 | PHASE2 |
| NCT00189579 | ARCAGY+ GINECO GROUP|Hoffmann-La Roche | Ovarian Cancer | | PHASE2 |
| NCT03242239 | Alteogen, Inc.|Cristália Produtos Químicos Farmacêuticos Ltda. | Healthy | 2016-02-09 | PHASE1 |
| NCT00118053 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Aventis Pharmaceuticals | Breast Cancer | 2005-04 | PHASE2 |
| NCT01401166 | Hoffmann-La Roche | Breast Neoplasms | 2011-10 | PHASE2 |
| NCT00038402 | M.D. Anderson Cancer Center|Genentech, Inc. | Breast Cancer | 2001-04 | PHASE3 |
| NCT00950300 | Hoffmann-La Roche | Breast Cancer | 2009-10-16 | PHASE3 |
| NCT06876714 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Early Stage Breast Carcinoma | 2025-09-17 | PHASE3 |
| NCT02721641 | Hoffmann-La Roche | Neoplasms | 1999-06 | PHASE3 |
| NCT06687928 | Celltrion | Healthy | 2025-03-26 | PHASE1 |
| NCT01004172 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Genentech, Inc. | Metastatic Breast Cancer|Breast Cancer|Progressive Breast Cancer | 2009-11 | PHASE2 |
| NCT03013504 | Prestige Biopharma Limited | HER2 Positive Breast Cancer | 2018-02-19 | PHASE3 |
| NCT02062983 | National Guard Health Affairs | Breast Cancer | 2012-06 | |
| NCT03879577 | University of Chicago | Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III | 2019-11-25 | PHASE2 |
| NCT00433095 | Ludwig-Maximilians - University of Munich|Pierre Fabre Laboratories | Carcinoma Breast Stage IV | | PHASE2 |
| NCT00005926 | National Cancer Institute (NCI) | Pancreatic Cancer|Pancreatic Neoplasm | 2000-06 | PHASE2 |
| NCT04109391 | Tanvex BioPharma USA, Inc. | HER2-positive Breast Cancer|Early-stage Breast Cancer|Breast Cancer|Breast Neoplasms|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2019-08-20 | PHASE3 |
| NCT00393783 | Memorial Sloan Kettering Cancer Center | Breast Cancer | 2006-05 | PHASE1 |
| NCT00681993 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Breast Cancer Research Foundation | Breast Cancer | 2008-04 | NA |
| NCT00493649 | US Oncology Research|Sanofi | Breast Cancer | 2007-06 | PHASE2 |
| NCT03433313 | EirGenix, Inc. | Breast Cancer | 2018-10-16 | PHASE3 |
| NCT04905667 | Genor Biopharma Co., Ltd. | Breast Cancer | 2019-11-13 | PHASE1 |
| NCT00191451 | Eli Lilly and Company | Breast Cancer | 2004-04 | PHASE2 |
| NCT00453635 | Hellenic Oncology Research Group|University Hospital of Crete | Breast Cancer | 2003-12 | PHASE2 |
| NCT00470847 | Nancy Lin, MD|Brigham and Women´s Hospital|Breast Cancer Research Foundation|GlaxoSmithKline | Breast Cancer|Brain Metastases | 2007-04 | PHASE1 |
| NCT01566721 | Hoffmann-La Roche | Breast Neoplasms | 2012-05-17 | PHASE3 |
| NCT00148681 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital | Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer | 2001-05 | PHASE2 |
| NCT00136539 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Genentech, Inc.|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Harvard Vanguard Medical Associates|Brigham and Women´s Hospital | Breast Cancer | 1999-03 | PHASE2 |
| NCT00496808 | M.D. Anderson Cancer Center | Ductal Carcinoma In Situ | 2005-03 | NA |
| NCT00148668 | Eric Winer, MD|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Yale University | Breast Cancer | 2003-12 | PHASE2 |
| NCT00041470 | University of Washington|Amgen|Bristol-Myers Squibb|GlaxoSmithKline | Breast Cancer | 2001-03 | PHASE1|PHASE2 |
| NCT03390608 | Karolinska Institutet|The Swedish Society of Medicine|The Swedish Breast Cancer Association (BRO)|Swedish Breast Cancer Group | Breast Cancer | 1977-01-01 | |
| NCT02748213 | Hoffmann-La Roche | Breast Cancer | 2002-02 | PHASE2 |
| NCT00943410 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2000-03 | PHASE2 |
| NCT04704934 | Daiichi Sankyo|AstraZeneca | Gastric Cancer, Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma | 2021-05-21 | PHASE3 |
| NCT03674112 | Hoffmann-La Roche | HER2-Positive Early Breast Cancer | 2018-12-19 | PHASE2 |
| NCT00520975 | National Cancer Institute (NCI) | Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer | 2007-11 | PHASE3 |
| NCT04644237 | Daiichi Sankyo|AstraZeneca | Non-Small Cell Lung Cancer | 2021-03-19 | PHASE2 |
| NCT02006667 | Hoffmann-La Roche | Urinary Tract Cancer | 2001-01 | PHASE2 |
| NCT05824975 | GI Innovation, Inc.|Merck Sharp & Dohme LLC | Advanced Solid Tumor|Metastatic Solid Tumor|Soft Tissue Sarcoma (STS)|Platinum-resistant Ovarian Cancer (PROC)|Hepatocellular Carcinoma (HCC)|Colorectal Cancer (CRC)|HER2 Negative Breast Cancer|Cutaneous Melanoma|Renal Cell Carcinoma (RCC) | 2023-05-30 | PHASE1|PHASE2 |
| NCT00667251 | Novartis Pharmaceuticals|NCIC Clinical Trials Group | Breast Cancer | 2008-10-07 | PHASE3 |
| NCT02654119 | University of Nebraska|National Cancer Institute (NCI) | HER2 Positive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7 | 2015-12-11 | PHASE2 |
| NCT06245356 | UNICANCER|Servier | Metastatic Colorectal Cancer|Metastatic Gastroesophageal Adenocarcinoma|DPD Deficiency | 2025-03-21 | PHASE2 |
| NCT00399529 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|American Cancer Society, Inc.|Avon Foundation|Cancer Treatment Research Foundation|The Commonwealth Fund|United States Department of Defense|Genentech, Inc. | Breast Neoplasms | 2006-09 | PHASE2 |
| NCT06630130 | Jeeyun Lee | Stomach Neoplasms | 2025-01-22 | PHASE2 |
| NCT05238831 | OHSU Knight Cancer Institute|Genentech, Inc.|Oregon Health and Science University | Advanced Breast Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Prostate Carcinoma|Advanced Sarcoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8 | 2023-01-30 | EARLY_PHASE1 |
| NCT00712881 | Cephalon, Inc. | Breast Cancer | 2008-10-13 | PHASE2 |
| NCT04556773 | AstraZeneca|Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Company, Limited | Metastatic Breast Cancer | 2020-12-17 | PHASE1 |
| NCT01774786 | Hoffmann-La Roche | Gastric Cancer | 2013-06-10 | PHASE3 |
| NCT07093931 | Shandong Cancer Hospital and Institute|Cancer Hospital Chinese Academy of Medical Science | Breast Cancer | 2025-08-01 | PHASE4 |
| NCT01641939 | Hoffmann-La Roche | Gastric Cancer | 2012-09-03 | PHASE2|PHASE3 |
| NCT02924883 | Hoffmann-La Roche | Metastatic Breast Cancer | 2016-09-26 | PHASE2 |
| NCT04290793 | Hebei Medical University Fourth Hospital | Breast Cancer | 2020-03-01 | PHASE2|PHASE3 |
| NCT03144947 | Gruppo Oncologico Italiano di Ricerca Clinica|University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit|University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology|University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione|Clirest s.r.l.|Mipharm SpA|Arithmos srl|Temas srl | Cancer, Breast | 2016-11-29 | PHASE2 |
| NCT04351230 | Academic and Community Cancer Research United|National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8 | 2020-11-11 | PHASE2 |
| NCT04481932 | Peking University | HER2-positive Breast Cancer | 2020-07 | PHASE2 |
| NCT00430001 | Danish Breast Cancer Cooperative Group|Hoffmann-La Roche|Sanofi | Breast Cancer | 2005-05 | PHASE3 |
| NCT06098898 | Base Therapeutics (Shanghai) Co., Ltd.|Shanghai 10th People´s Hospital | Gastric Cancer | 2023-11-01 | EARLY_PHASE1 |
| NCT00515411 | Memorial Sloan Kettering Cancer Center|Sanofi|Roche-Genentech|City of Hope National Medical Center|Piedmont Hospital Research Institute|Medical College of Wisconsin|Queens Health Network|Weill Medical College of Cornell University|Memorial Cancer Institute, Florida|University of Pittsburgh|Long Island Jewish Medical Center|Nebraska Cancer Specialists Methodist Estabrook Cancer Center | Gastroesophageal Junction Adenocarcinoma|Gastric Cancer | 2006-10-23 | PHASE2 |
| NCT07413939 | Hoffmann-La Roche | HER2-positive Breast Cancer | 2026-04-30 | PHASE2|PHASE3 |
| NCT05474690 | Henan Cancer Hospital | Breast Cancer|HER2-positive Breast Cancer | 2022-05-11 | PHASE3 |
| NCT04629846 | Qilu Pharmaceutical Co., Ltd. | Breast Cancer | 2020-11-23 | PHASE3 |
| NCT07203729 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | HER2-Low Unresectable+Metastatic Breast Cancer Complicated With Visceral Crisis | 2026-03-01 | PHASE2 |
| NCT01513083 | Hoffmann-La Roche | Breast Cancer | 2012-02 | PHASE1 |
| NCT06435429 | Jazz Pharmaceuticals | Metastatic HER2-positive Breast Cancer | 2024-08-13 | PHASE3 |
| NCT05319873 | Jonsson Comprehensive Cancer Center|Seagen Inc.|Novartis | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Locally Advanced HER2-Positive Breast Carcinoma|Metastatic HER2-Positive Breast Carcinoma|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8 | 2022-04-07 | PHASE1|PHASE2 |
| NCT04379596 | AstraZeneca|Daiichi Sankyo | Gastric Cancer | 2020-06-03 | PHASE2 |
| NCT03365882 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7 | 2017-11-27 | PHASE2 |
| NCT00755313 | University of California, San Francisco|National Cancer Institute (NCI) | Breast Cancer|Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Neurotoxicity|Psychosocial Effects of Cancer and Its Treatment | 2007-05 | |
| NCT03457896 | NSABP Foundation Inc|Puma Biotechnology, Inc. | Metastatic Colorectal Cancer | 2018-05-18 | PHASE2 |
| NCT01419197 | Hoffmann-La Roche | Breast Cancer | 2011-09 | PHASE3 |
| NCT01959386 | Hoffmann-La Roche | Breast Neoplasms | 2013-11-07 | |
| NCT01750073 | University of Nebraska|National Cancer Institute (NCI) | Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|HER2+Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma | 2012-12-07 | PHASE2 |
| NCT07497386 | Jiangsu HengRui Medicine Co., Ltd. | Unresectable Locally Recurrent Breast Cancer|Unresectable Locally Metastatic Breast Cancer | 2026-04 | PHASE2 |
| NCT00615602 | Hellenic Oncology Research Group|University Hospital of Crete | Breast Cancer | 2004-10 | PHASE3 |
| NCT00004888 | National Cancer Institute (NCI) | Recurrent Breast Cancer|Stage IV Breast Cancer | 2001-01 | PHASE2 |
| NCT02725541 | Jenny C. Chang, MD|Genentech, Inc.|The Methodist Hospital Research Institute | Breast Cancer | 2016-03 | PHASE2 |
| NCT07037199 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Advanced Breast Cancer | 2025-08-18 | PHASE2 |
| NCT04993014 | AC Camargo Cancer Center | Breast Neoplasms|HER2-positive Breast Cancer|Circulating Tumor Cell | 2021-03-01 | PHASE2 |
| NCT03297606 | Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer|Seagen Inc. | Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors | 2018-03-23 | PHASE2 |
| NCT00550771 | Merck Sharp & Dohme LLC | Breast Neoplasm | 2007-07-16 | PHASE2 |
| NCT01428414 | Zhimin Shao|Roche Pharma AG | HER-2 Positive Breast Cancer | 2011-08 | PHASE2 |
| NCT04510285 | Memorial Sloan Kettering Cancer Center | Esophagogastric Tumors|Gastric Cancer|Gastric Tumor|Esophageal Cancer|Esophageal Neoplasms|Esophageal Tumor|GastroEsophageal Cancer|Gastroesophageal Junction Adenocarcinoma|Gastroesophageal Junction Tumor|Gastroesophageal Junction Cancer | 2020-08-10 | PHASE2 |
| NCT06650332 | Zhejiang Cancer Hospital | Metastatic HER2 Positive Gastroesophageal Junction Cancer | 2024-07-10 | PHASE1|PHASE2 |
| NCT05525858 | Seoul National University Bundang Hospital|Korean Cancer Study Group|Roche Pharma AG | Solid Tumor|Advanced Solid Tumor|Metastatic Cancer | 2022-09-28 | |
| NCT05356897 | Academic and Community Cancer Research United|National Cancer Institute (NCI) | Metastatic Colon Adenocarcinoma|Metastatic Colorectal Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Stage IV Colon Cancer AJCC V8|Stage IV Colorectal Cancer AJCC V8|Stage IV Rectal Cancer AJCC V8 | 2023-10-31 | PHASE2 |
| NCT00885755 | Hoffmann-La Roche | Breast Cancer | 2009-08-13 | PHASE2 |
| NCT05415215 | Hoffmann-La Roche | Early Breast Cancer|Locally Advanced Breast Cancer|Inflammatory Breast Cancer | 2022-07-05 | PHASE3 |
| NCT00005842 | National Cancer Institute (NCI) | Cancer | 2000-06 | PHASE1 |
| NCT03765983 | Dana-Farber Cancer Institute|Kazia Therapeutics Limited | Breast Cancer | 2019-02-11 | PHASE2 |
| NCT05945927 | Hoffmann-La Roche | Breast Cancer | 2023-09-13 | |
| NCT00288002 | GBG Forschungs GmbH | Breast Cancer | 2005-01 | PHASE3 |
| NCT06589830 | Suzhou Teligene Ltd. | Colorectal Cancer Metastatic|Advanced Colorectal Cancer | 2025-05-13 | PHASE2 |
| NCT05800275 | UNICANCER|Seagen Inc. | Leptomeningeal Metastasis|Leptomeningeal Disease|HER2-positive Metastatic Breast Cancer | 2023-12-18 | PHASE2 |
| NCT01325207 | Northwestern University | Breast Cancer | 2011-08-01 | PHASE1|PHASE2 |
| NCT02598427 | Kimberly Blackwell | HER2 Positive Untreated Metastatic Breast Cancer|Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer | 2017-05-01 | PHASE1 |
| NCT00781612 | Genentech, Inc.|Hoffmann-La Roche | Neoplasm Metastasis | 2008-10-16 | PHASE2 |
| NCT01526369 | Cancer Trials Ireland | Metastatic Breast Cancer | 2012-02-13 | PHASE3 |
| NCT02167854 | Memorial Sloan Kettering Cancer Center|Novartis | Breast Cancer | 2014-06-16 | PHASE1 |
| NCT06348134 | University of Chicago | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|HER2-positive Breast Cancer|Breast Cancer | 2025-03-18 | PHASE2 |
| NCT01340430 | Lucia Del Mastro,MD | HER-2 Positive Breast Cancer | 2011-03 | PHASE2 |
| NCT03425656 | AryoGen Pharmed Co. | Malignant Neoplasm of Breast | 2016-07-09 | PHASE3 |
| NCT00130507 | Spanish Breast Cancer Research Group|Hoffmann-La Roche | Breast Cancer | 2005-11-04 | PHASE2 |
| NCT00103233 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Breast Cancer | 2004-12 | PHASE3 |
| NCT01170143 | Fudan University|Hoffmann-La Roche | Breast Cancer | 2009-08 | PHASE2 |
| NCT01894711 | Maastricht University Medical Center | Breast Cancer | 2010-05 | |
| NCT01344863 | Hoffmann-La Roche | Healthy Volunteer | 2011-04 | PHASE1 |
| NCT00726180 | University of Michigan Rogel Cancer Center | Breast Cancer | 2008-07 | PHASE1|PHASE2 |
| NCT01480674 | Hoffmann-La Roche | Breast Cancer | 2011-03-28 | |
| NCT03273595 | Xijing Hospital | Neoplasms, Breast | 2016-07 | PHASE2 |
| NCT00004883 | National Cancer Institute (NCI) | Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer | 2000-02 | PHASE2 |
| NCT02625441 | Helsinki University Central Hospital | Breast Cancer | 2015-12 | PHASE3 |
| NCT05553522 | Baptist Health South Florida|Pfizer | Brain Metastases|HER2-positive Breast Cancer | 2024-01-29 | PHASE1 |
| NCT03319459 | Fate Therapeutics | HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreatic Cancer|Melanoma | 2018-01-18 | PHASE1 |
| NCT02213289 | University of Chicago|AbbVie | Adenocarcinoma | 2015-01-20 | PHASE2 |
| NCT04819971 | The First Affiliated Hospital of Zhengzhou University | Stomach Cancer | 2021-12-01 | PHASE2 |
| NCT00057993 | Northwestern University|National Cancer Institute (NCI) | Breast Cancer | 2002-07 | PHASE2 |
| NCT07528898 | Hebei Medical University Fourth Hospital|Jiangsu Hengrui Pharmaceutical Co., Ltd. | Breast Cancer | 2026-05 | PHASE2 |
| NCT01242449 | Vejle Hospital | Breast Cancer | 2010-11 | PHASE2 |
| NCT03239015 | Baodong Qin | Rare Tumor|Refractory Tumor | 2017-01-01 | PHASE2 |
| NCT07047755 | Henan Cancer Hospital | Breast Cancer | 2025-07-01 | PHASE2 |
| NCT01120184 | Hoffmann-La Roche|Genentech, Inc. | Breast Cancer | 2010-07-31 | PHASE3 |
| NCT03523585 | Daiichi Sankyo|Daiichi Sankyo Co., Ltd.|AstraZeneca | Breast Cancer | 2018-08-01 | PHASE3 |
| NCT00796978 | Cynthia Owusu, MD | Breast Cancer | 2009-02-05 | PHASE2 |
| NCT06470347 | Zunyi Medical College | HER-2 Positive Advanced Breast Cancer | 2022-11-01 | PHASE1|PHASE2 |
| NCT00436566 | Mayo Clinic|National Cancer Institute (NCI) | Breast Cancer|Cardiac Toxicity | 2007-03-16 | PHASE2 |
| NCT06162559 | The Netherlands Cancer Institute|Seagen Inc. | Breast Cancer | 2023-12-18 | PHASE1 |
| NCT03501979 | University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Johns Hopkins University|Seagen Inc.|University of Michigan|Georgetown University|University of California, San Francisco|University of Chicago|Indiana University|University of Washington|University of Texas | Metastatic Breast Cancer|Leptomeningeal Disease | 2019-02-20 | PHASE2 |
| NCT05912062 | Institut Català d´Oncologia|Instituto de Salud Carlos III|Fundación Sociedad Espa?ola de Oncologia Médica|Institut d´Investigacions Biomèdiques August Pi i Sunyer|Reveal Genomics (Registered trademark) | HER2-positive Breast Cancer|Neoplasms|Breast Cancer | 2021-03-22 | |
| NCT03910712 | Peking Union Medical College Hospital | Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor | 2019-06-01 | PHASE2 |
| NCT02162667 | Celltrion|Nippon Kayaku Co., Ltd. | HER2-positive Carcinoma of Breast | 2014-06 | PHASE3 |
| NCT04917900 | West China Hospital | Breast Cancer | 2020-12-01 | PHASE2 |
| NCT01388647 | Vector Oncology|Eisai Inc. | HER-2 Positive Breast Cancer | 2011-08 | PHASE1|PHASE2 |
| NCT00821886 | SCRI Development Innovations, LLC|Bristol-Myers Squibb|Genentech, Inc. | Breast Cancer | 2009-02 | PHASE2 |
| NCT04509596 | Dizal Pharmaceuticals | Breast Cancer Metastatic | 2020-09-21 | PHASE1 |
| NCT02843126 | Fuda Cancer Hospital, Guangzhou|Shenzhen Hank Bioengineering Institute | Recurrent Breast Cancer | 2016-07-01 | PHASE1|PHASE2 |
| NCT04150640 | University of Wisconsin, Madison|Ipsen | Esophageal Adenocarcinoma|Gastric Adenocarcinoma | 2020-07-13 | PHASE2 |
| NCT03264547 | Japan Breast Cancer Research Group|Eisai Co., Ltd. | Breast Cancer | 2017-08-28 | PHASE3 |
| NCT04494425 | AstraZeneca|Daiichi Sankyo | Advanced or Metastatic Breast Cancer | 2020-07-24 | PHASE3 |
| NCT06107790 | Zhejiang Hisun Pharmaceutical Co. Ltd. | HER2-positive Breast Cancer | 2018-05-16 | PHASE3 |
| NCT07318389 | M.D. Anderson Cancer Center | Dynamic Tumor Resistance|Metastatic Colorectal Cancer | 2026-06-10 | EARLY_PHASE1 |
| NCT05376878 | City of Hope Medical Center|National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain | 2022-12-21 | PHASE4 |
| NCT01196390 | National Cancer Institute (NCI)|NRG Oncology | Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Cancer AJCC v7|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7 | 2011-02-14 | PHASE3 |
| NCT03043313 | Seagen Inc.|National Cancer Institute (NCI)|Academic and Community Cancer Research United | Metastatic Colorectal Adenocarcinoma | 2017-06-23 | PHASE2 |
| NCT06846996 | Daiichi Sankyo | HER2-positive Gastric Cancer|HER2-positive Gastroesophageal Junction | 2025-02-27 | |
| NCT06797622 | Fudan University | Breast Cancer|Metastatic Breast Cancer | 2025-02-15 | PHASE2 |
| NCT05965479 | University of Southampton|AstraZeneca|Natera, Inc. | Gastrooesophageal Cancer | 2024-04-10 | PHASE2 |
| NCT07012031 | National Cancer Institute (NCI) | Locally Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8 | 2026-08-07 | PHASE1|PHASE2 |
| NCT05583110 | Spanish Breast Cancer Research Group|Seagen Inc. | HER2-positive Metastatic Breast Cancer|Locally Advanced HER2 Positive Breast Carcinoma | 2023-03-08 | PHASE2 |
| NCT06021379 | AryoGen Pharmed Co. | Breast Cancer | 2017-02-22 | |
| NCT04886531 | Ruth O´Regan|Puma Biotechnology, Inc.|University of Rochester | Breast Cancer|HER2-positive Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer | 2022-07-21 | PHASE2 |
| NCT02665637 | Celltrion | Healthy Volunteers | 2015-12 | PHASE1 |
| NCT01363986 | Hoffmann-La Roche | Breast Cancer | 2011-09 | PHASE2 |
| NCT01779050 | Washington University School of Medicine|Genentech, Inc. | Breast Neoplasms | 2013-12-19 | PHASE2 |
| NCT07118527 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma | 2025-08-18 | PHASE3 |
| NCT01853748 | Dana-Farber Cancer Institute | Breast Cancer | 2013-05 | PHASE2 |
| NCT07246317 | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 2025-12-15 | PHASE2 |
| NCT00679341 | Hoffmann-La Roche | Breast Cancer | 2008-09 | PHASE2 |
| NCT04717531 | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 2021-06-03 | PHASE2 |
| NCT05841381 | Fudan University | Breast Cancer | 2023-05-06 | PHASE3 |
| NCT04294628 | National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm | 2020-09-01 | PHASE1 |
| NCT05076695 | Fudan University | Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer | 2021-10-15 | PHASE2 |
| NCT04341181 | Ulrik Lassen|Roche Pharma AG|Pfizer|GlaxoSmithKline | Cancer|Tumors|Neoplasms|Neoplasia | 2020-08-24 | PHASE2 |
| NCT01772472 | Hoffmann-La Roche|NSABP Foundation Inc|GBG Forschungs GmbH | Breast Cancer | 2013-04-03 | PHASE3 |
| NCT05193292 | Fudan University | Colorectal Neoplasms|Intestinal Neoplasms | 2022-01 | PHASE2 |
| NCT04014075 | Daiichi Sankyo|AstraZeneca | Adenocarcinoma Gastric Stage IV With Metastases|Adenocarcinoma - GEJ | 2019-11-26 | PHASE2 |
| NCT04152057 | West China Hospital|Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer|HER2 Positive|Combination Chemotherapy | 2019-11 | PHASE1|PHASE2 |
| NCT00397501 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Brain and Central Nervous System Tumors|Breast Cancer|Cognitive+Functional Effects|Drug+Agent Toxicity by Tissue+Organ|Psychosocial Effects of Cancer and Its Treatment | 2013-10 | PHASE1|PHASE2 |
| NCT00387907 | Sanofi | Advanced Breast Cancer|Breast Cancer|Metastatic Breast Cancer | 2006-10 | PHASE2 |
| NCT02139358 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. | Breast Cancer | 2014-09-05 | PHASE1|PHASE2 |
| NCT05901935 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Advanced Breast Cancer | 2023-07 | PHASE3 |
| NCT00171847 | Novartis Pharmaceuticals|Roche - Prof. Dr. Jens Huober et al. | Metastatic Breast Cancer | 2003-03 | PHASE4 |
| NCT05720026 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 2023-01-09 | PHASE3 |
| NCT06832904 | First Affiliated Hospital of Zhejiang University | HER2-positive Breast Cancer|Neoadjuvant Therapy|Pyrotinib | 2024-12-03 | PHASE2 |
| NCT03199885 | National Cancer Institute (NCI)|NRG Oncology | Metastatic Breast Adenocarcinoma|Metastatic HER2-Positive Breast Carcinoma|Recurrent Breast Adenocarcinoma|Recurrent HER2-Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Breast Carcinoma|Unresectable HER2-Positive Breast Carcinoma | 2019-04-05 | PHASE3 |
| NCT03364348 | George W. Sledge Jr.|National Cancer Institute (NCI) | HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2017-10-30 | PHASE1 |
| NCT04208178 | Novartis Pharmaceuticals | Advanced HER2&addition;Breast Cancer | 2020-07-16 | PHASE3 |
| NCT06035679 | Youzhi Zhu | Breast Cancer Female | 2023-08-17 | NA |
| NCT01964391 | Hoffmann-La Roche | Breast Cancer | 2014-02-21 | PHASE3 |
| NCT00398489 | Technical University of Munich | Breast Cancer | 2006-10 | PHASE2 |
| NCT05395052 | Fate Therapeutics | Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer | 2022-05-31 | PHASE1 |
| NCT07368543 | Fudan University | Metastatic Breast Cancer | 2026-01-16 | PHASE2 |
| NCT04873362 | Hoffmann-La Roche | Breast Cancer | 2021-05-04 | PHASE3 |
| NCT00232479 | University of Miami|Aventis Pharmaceuticals | Breast Cancer | 2005-09 | PHASE2 |
| NCT04034823 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Breast Cancer | 2019-09-01 | PHASE2 |
| NCT01966471 | Hoffmann-La Roche | Breast Cancer | 2014-01-31 | PHASE3 |
| NCT01969643 | Seagen Inc. | HER2 Positive Breast Neoplasms|Hormone Receptor Positive Breast Neoplasms|Triple Negative Breast Neoplasms|HER2 Mutations Breast Neoplasms | 2013-10-22 | PHASE1 |
| NCT04962425 | Peking University Third Hospital | Cardiac Toxicity|Antitumor Drugs|Breast Cancer | 2021-01-08 | |
| NCT03112590 | H. Lee Moffitt Cancer Center and Research Institute|Horizon Pharma Ireland, Ltd., Dublin Ireland | Breast Cancer|Breast Cancer, Male|Breast Cancer Female|HER2-positive Breast Cancer | 2017-06-23 | PHASE1|PHASE2 |
| NCT04670796 | Shanghai Henlius Biotech | Healthy | 2021-03-02 | PHASE1 |
| NCT02379585 | Western Regional Medical Center | HER2-positive Breast Cancer | 2013-01 | PHASE1|PHASE2 |
| NCT01613482 | Centre Oscar Lambret | Breast Cancer|Metastasis|Sur-expressing Her2-neu | 2008-01 | PHASE3 |
| NCT01386580 | BBB-Therapeutics B.V. | Brain Metastases|Lung Cancer|Breast Cancer|Melanoma|Malignant Glioma | 2011-07 | PHASE1|PHASE2 |
| NCT01265927 | Indiana University|Breast Cancer Research Foundation|Geron Corporation | Breast Neoplasms | 2011-01 | PHASE1 |
| NCT00820222 | Novartis Pharmaceuticals | Metastases, Brain | 2009-04-14 | PHASE3 |
| NCT02514681 | Japan Breast Cancer Research Group|Chugai Pharmaceutical | HER2-positive Locally Advanced or Metastatic Breast Cancer | 2015-08-01 | PHASE3 |
| NCT01275677 | National Cancer Institute (NCI)|NRG Oncology | HER2+Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2011-02-08 | PHASE3 |
| NCT02314481 | University College, London|Hoffmann-La Roche | Non-small Cell Lung Cancer | 2017-05-12 | PHASE2 |
| NCT03994107 | Peking Union Medical College|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2019-10-01 | PHASE1|PHASE2 |
| NCT00426556 | Novartis Pharmaceuticals | Metastatic Breast Cancer | 2007-07 | PHASE1 |
| NCT02789657 | Brown University|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital | Breast Cancer | 2016-11-21 | PHASE2 |
| NCT03742102 | AstraZeneca | Triple Negative Breast Neoplasms | 2018-12-21 | PHASE1|PHASE2 |
| NCT05228951 | Shengjing Hospital | Breast Cancer | 2022-02-10 | PHASE2 |
| NCT07179939 | Fudan University|Jiangsu HengRui Medicine Co., Ltd.|Chinese PLA General Hospital | HER2-positive Breast Cancer | 2025-09-10 | PHASE2 |
| NCT06989112 | AstraZeneca|Daiichi Sankyo Co., Ltd.|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) | Endometrial Cancer | 2025-03-27 | PHASE3 |
| NCT01904903 | Medstar Health Research Institute|Genentech, Inc. | HER2 Positive Breast Cancer|Left Ventricular Function Systolic Dysfunction | 2013-10 | PHASE2 |
| NCT00670982 | Harold J. Burstein, MD, PhD|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc.|New Hampshire Oncology-Hematology PA|Lowell General Hospital|Hartford Hospital | Breast Cancer | 2008-05 | PHASE2 |
| NCT04220203 | Seagen, a wholly owned subsidiary of Pfizer|Parexel | HER2-positive Breast Cancer | | |
| NCT05417594 | AstraZeneca | Advanced Solid Malignancies | 2022-06-24 | PHASE1|PHASE2 |
| NCT03368729 | University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Tesaro, Inc.|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation of Alabama|The V Foundation | Metastatic Breast Cancer|HER2 Positive Breast Carcinoma | 2019-09-06 | PHASE1|PHASE2 |
| NCT07421141 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Breast Cancer|HER2-positive Breast Cancer|Early Breast Cancer | 2023-09-01 | PHASE2 |
| NCT07007559 | ALX Oncology Inc. | Breast Cancer, Metastatic | 2025-12-10 | PHASE2 |
| NCT06585969 | Danish Breast Cancer Cooperative Group | Metastatic Breast Cancer|ER-positive Breast Cancer|Luminal B|Her2 Enriched|Basal Like | 2026-01-01 | PHASE3 |
| NCT04457596 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Seagen Inc. | Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Synchronous Bilateral Breast Carcinoma | 2021-03-02 | PHASE3 |
| NCT07309770 | Sheng Zhang | Urachal Cancer|Advanced Solid Tumor Cancer|Antibody-drug Conjugates | 2025-12-18 | PHASE2 |
| NCT06331169 | Fudan University | Breast Cancer | 2024-07-31 | PHASE1 |
| NCT05207722 | Celularity Incorporated | Metastatic HER2 Positive Gastroesophageal Junction Cancer | 2022-04-14 | PHASE1|PHASE2 |
| NCT02624973 | Haukeland University Hospital|Helse Vest|Pfizer|AstraZeneca | Breast Cancer | 2016-04-15 | PHASE2 |
| NCT02689921 | Midwestern Regional Medical Center | Breast Neoplasms | 2016-04 | PHASE2 |
| NCT00003881 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Lung Cancer | 1999-05 | PHASE2 |
| NCT01855828 | Yale University|Genentech, Inc. | Her2-Positive Breast Cancer | 2013-09 | PHASE2 |
| NCT04893109 | Dana-Farber Cancer Institute|Genentech, Inc. | Breast Cancer|HER2-positive Breast Cancer | 2021-06-16 | PHASE2 |
| NCT01827163 | Memorial Sloan Kettering Cancer Center|GlaxoSmithKline | HER2-Positive Early Stage Breast Cancer | 2013-04 | PHASE2 |
| NCT01702571 | Hoffmann-La Roche | Breast Cancer | 2012-11-27 | PHASE3 |
| NCT07545044 | Shanghai JMT-Bio Inc. | HER2-positive Recurrent or Metastatic Breast Cancer | 2026-05-30 | PHASE2 |
| NCT01912963 | Dana-Farber Cancer Institute|Eisai Inc.|Genentech, Inc. | HER2-positive Breast Cancer|Metastatic Breast Cancer | 2013-09 | PHASE2 |
| NCT06537674 | Jiangsu Famous Medical Technology Co., Ltd. | HER2&addition; Breast Cancer | 2024-08-15 | |
| NCT00093808 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Breast Cancer | 2004-08 | PHASE2 |
| NCT05672524 | Memorial Sloan Kettering Cancer Center | Adenocarcinoma of the Rectum|Locally Advanced Rectal Adenocarcinoma|Rectal Adenocarcinoma|HER2 Positive Rectal Adenocarcinoma|Rectal Cancer | 2022-12-30 | PHASE2 |
| NCT04088110 | Fuzhou General Hospital | Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor | 2019-11 | PHASE2 |
| NCT04680442 | Population Health Research Institute | Breast Cancer|Heart Failure | 2021-07-01 | PHASE2 |
| NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical | Breast Cancer | 2019-01-11 | PHASE3 |
| NCT06441890 | University of Illinois at Chicago | Breast Cancer|HER2-positive Breast Cancer | 2024-12-05 | PHASE2 |
| NCT02678182 | Royal Marsden NHS Foundation Trust|MedImmune LLC|Clovis Oncology, Inc.|Eli Lilly and Company|AstraZeneca | Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Gastro-oesophageal Junction|Adenocarcinoma of the Stomach | 2015-02 | PHASE2 |
| NCT06278870 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Metastatic Breast Cancer|First-line Treatment | 2023-09-06 | PHASE3 |
| NCT01950182 | Sun Yat-sen University | Breast Cancer | 2013-09-16 | PHASE3 |
| NCT00464646 | NSABP Foundation Inc|Genentech, Inc.|International Drug Development Institute | Breast Cancer | 2007-05 | PHASE2 |
| NCT01285466 | Novartis Pharmaceuticals | Metastatic or Locally Advanced Solid Tumors | 2011-01 | PHASE1 |
| NCT05795101 | Filipa Lynce, MD|AstraZeneca|Daiichi Sankyo | Invasive Breast Cancer|Inflammatory Breast Cancer Stage III|HER2-positive Breast Cancer|HER2 Low Breast Adenocarcinoma|Breast Cancer | 2023-05-04 | PHASE2 |
| NCT06130007 | Xuekui Liu | Oral Squamous Cell Carcinoma | 2023-11-25 | PHASE2 |
| NCT05800756 | Yantai Yuhuangding Hospital|Jiangsu Hengrui Pharmaceutical Co., Ltd. | Breast Cancer | 2022-08-04 | PHASE2 |
| NCT05091528 | Silverback Therapeutics | HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer | 2022-02-08 | PHASE1|PHASE2 |
| NCT05318339 | Chinese Academy of Medical Sciences | Carcinoma, Transitional Cell|HER-2 Gene Amplification | 2022-03-10 | PHASE2 |
| NCT03084939 | Hoffmann-La Roche | Breast Cancer | 2017-04-24 | PHASE3 |
| NCT00003539 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 1998-04 | PHASE2 |
| NCT03742986 | NYU Langone Health | Breast Cancer | 2019-05-02 | PHASE2 |
| NCT00736970 | Merck Sharp & Dohme LLC | Breast Cancer|Breast Neoplasms | 2008-07 | PHASE2 |
| NCT06649331 | Fudan University | Advanced Breast Cancer|Metastatic Breast Cancer|Triple Negative Breast Cancer (TNBC)|HER2-negative Breast Cancer|Breast Cancer | 2024-10-21 | PHASE2 |
| NCT04931342 | Hoffmann-La Roche|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) | Ovarian Cancer | 2021-10-07 | PHASE2 |
| NCT07518173 | Sichuan Baili Pharmaceutical Co., Ltd.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 2026-04 | PHASE3 |
| NCT00024154 | National Cancer Institute (NCI) | Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer | 2002-02 | PHASE2 |
| NCT02390427 | Otto Metzger, MD|Genentech, Inc. | Metastatic Breast Cancer|Recurrent Breast Cancer | 2015-04-20 | PHASE1 |
| NCT05515796 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Immunotherapy|Gastric Cancer|Rectal Cancer|Chemotherapy Effect|Radiotherapy | 2022-09-01 | PHASE2 |
| NCT05002127 | ALX Oncology Inc.|Eli Lilly and Company | Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma | 2022-01-15 | PHASE2|PHASE3 |
| NCT05955170 | Institut Curie|Seagen Inc. | HER2-positive Breast Cancer | 2023-12-19 | PHASE2 |
| NCT01276041 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|University of Pennsylvania | Breast Cancer | 2011-01-05 | PHASE2 |
| NCT03521245 | OmicsWay Corp.|Oncobox Ltd., Russia|Vitamed LLC, Russia|Republican Oncological Dispensary of Karelia Republic, Russia | HER2-positive Breast Cancer | 2017-10-01 | |
| NCT05385705 | Vall d´Hebron Institute of Oncology|Clinica Universidad de Navarra, Universidad de Navarra|Puerta de Hierro University Hospital|Hospital del Mar|Banc de Sang i Teixits | Breast Neoplasms | 2022-05-11 | PHASE1 |
| NCT00807859 | Amgen | Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors | 2009-03-09 | PHASE1 |
| NCT00639366 | Anglo Celtic Cooperative Oncology Group | Breast Cancer | 2007-02 | PHASE3 |
| NCT05560308 | Tianjin Medical University Cancer Institute and Hospital | HER2&addition; Advanced Breast Cancer Patients Progressing on TKI Therapy | 2022-09-30 | NA |
| NCT04298918 | Hoffmann-La Roche | Breast Cancer | 2020-09-23 | PHASE1|PHASE2 |
| NCT00134680 | Duke University|Genentech, Inc.|Novartis Pharmaceuticals | Metastatic Breast Cancer | 2000-01 | PHASE2 |
| NCT04487236 | Suzhou Zanrong Pharma Limited | Advanced Solid Tumors|HER2-positive Breast Cancer | 2020-10-15 | PHASE1 |
| NCT00041067 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Breast Cancer | 2002-09 | PHASE2 |
| NCT03095352 | Laura Huppert, MD, BA|Mayo Clinic|Johns Hopkins University|Translational Breast Cancer Research Consortium|Massachusetts General Hospital|Merck Sharp & Dohme LLC | Breast Cancer|Chest Wall Disease | 2017-09-02 | PHASE2 |
| NCT07245797 | Zhimin Shao | Breast Cancer | 2025-12-15 | PHASE2 |
| NCT00126607 | National Cancer Institute (NCI) | High-grade Salivary Gland Mucoepidermoid Carcinoma|Recurrent Salivary Gland Cancer|Salivary Gland Acinic Cell Tumor|Salivary Gland Adenocarcinoma|Salivary Gland Poorly Differentiated Carcinoma|Stage IVA Salivary Gland Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer | 2005-07 | PHASE2 |
| NCT00054587 | UNICANCER | Breast Cancer | 2001-06 | PHASE3 |
| NCT00006110 | UNC Lineberger Comprehensive Cancer Center | Breast Cancer | 1998-12 | PHASE2 |
| NCT05931042 | Rawalpindi Medical College | HER2&addition; Breast Cancer | 2023-06-01 | |
| NCT05577442 | Peking University Cancer Hospital & Institute | Breast Neoplasm Female | 2022-10-20 | PHASE2 |
| NCT01796197 | Dana-Farber Cancer Institute | Breast Cancer | 2013-08 | PHASE2 |
| NCT00485979 | Sanofi | Breast Neoplasms | 2007-06 | PHASE2 |
| NCT06245824 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 2024-01-30 | PHASE4 |
| NCT00238420 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group | Bladder Urothelial Carcinoma|Stage I Bladder Cancer AJCC v6 and v7|Stage II Bladder Cancer AJCC v6 and v7|Stage III Bladder Cancer AJCC v6 and v7 | 2005-07-26 | PHASE1|PHASE2 |
| NCT05633979 | M.D. Anderson Cancer Center|Daiichi Sankyo | Breast Cancer | 2023-02-09 | PHASE1 |
| NCT02402712 | Hoffmann-La Roche | Breast Cancer | 2015-05-06 | PHASE3 |
| NCT07136428 | Duke University|Novartis | HER2&addition; Metastatic Breast Cancer | 2026-07 | PHASE1|PHASE2 |
| NCT00915018 | Puma Biotechnology, Inc. | Breast Cancer | 2009-08-21 | PHASE2 |
| NCT04108858 | National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|HER2-Positive Breast Carcinoma|Metastatic Breast Carcinoma | 2021-05-20 | PHASE1|PHASE2 |
| NCT00949247 | Case Comprehensive Cancer Center | Breast Cancer | 2009-12 | EARLY_PHASE1 |
| NCT04266249 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI) | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8 | 2020-03-13 | PHASE2 |
| NCT06899126 | Daiichi Sankyo|Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer | 2025-10-24 | PHASE3 |
| NCT02393248 | Incyte Corporation | Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN | 2015-02-27 | PHASE1|PHASE2 |
| NCT03784599 | The Netherlands Cancer Institute|AstraZeneca|Roche Pharma AG | Carcinoma, Non-Small-Cell Lung | 2018-12-18 | PHASE2 |
| NCT00216047 | Hoosier Cancer Research Network|Novartis Pharmaceuticals|Walther Cancer Institute | Breast Cancer | 2005-01 | PHASE1|PHASE2 |
| NCT04398914 | Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer Invasive | 2020-05-30 | PHASE2 |
| NCT03125928 | Fox Chase Cancer Center|Genentech, Inc. | HER2-positive Breast Cancer | 2017-06-13 | PHASE2 |
| NCT02238509 | Consorzio Oncotech|Clinical Research Technology S.r.l. | Metastatic Breast Cancer | 2014-11 | PHASE2 |
| NCT03094052 | University of California, San Francisco|Puma Biotechnology, Inc. | HER2-positive Breast Cancer|Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2018-10-09 | PHASE2 |
| NCT01491737 | Hoffmann-La Roche | Breast Cancer | 2012-02-17 | PHASE2 |
| NCT02066532 | Dawn L. Hershman|Incyte Corporation|National Cancer Institute (NCI) | Metastatic Breast Cancer|Breast Carcinoma|HER-2 Positive Breast Cancer | 2014-06 | PHASE1|PHASE2 |
| NCT06231693 | AstraZeneca|Hospital Israelita Albert Einstein | Breast Cancer | 2023-12-04 | |
| NCT01304784 | Merrimack Pharmaceuticals | HER-2 Gene Amplification | 2011-01 | PHASE1 |
| NCT02658734 | Hoffmann-La Roche | HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer | 2016-11-01 | PHASE4 |
| NCT02250209 | Chinese PLA General Hospital | Gastric Cancer | 2014-07 | PHASE2 |
| NCT05582499 | Fudan University | Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2022-11-01 | PHASE2 |
| NCT07176702 | Shanghai Zhongshan Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Metastatic PDAC|HER2-positive Status | 2025-09-30 | PHASE2 |
| NCT03783936 | Ashwin Somasundaram|EMD Serono|University of North Carolina, Chapel Hill | Gastric Adenocarcinoma|Esophageal Adenocarcinoma|Metastasis|HER-2 Gene Amplification | 2019-01-24 | PHASE2 |
| NCT05980481 | RemeGen Co., Ltd. | Gastric Cancer | 2023-08-04 | PHASE2|PHASE3 |
| NCT01971515 | EMD Serono | Solid Tumor | 2013-12-13 | PHASE1 |
| NCT00379015 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Breast Cancer | 2006-01 | PHASE2 |
| NCT03767335 | Menarini Group | Advanced or Metastatic Breast Cancer | 2018-11-13 | PHASE1 |
| NCT03367676 | Ruijin Hospital | Breast Cancer | 2017-12-30 | PHASE2 |
| NCT00003740 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Prostate Cancer | 1998-10 | PHASE2 |
| NCT02569489 | HUYABIO International, LLC. | Breast Cancer | 2015-12 | PHASE1 |
| NCT00968968 | Novartis Pharmaceuticals | Cancer | 2010-01-20 | PHASE3 |
| NCT03101748 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Breast Inflammatory Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 | 2018-02-19 | PHASE1|PHASE2 |
| NCT05325632 | H. Lee Moffitt Cancer Center and Research Institute|ImmunoRestoration | HER2-positive Breast Cancer | 2021-10-28 | PHASE2 |
| NCT07187752 | Shandong Cancer Hospital and Institute | Breast Cancer | 2025-09-30 | NA |
| NCT00047255 | Jonsson Comprehensive Cancer Center | Breast Cancer | 2002-05 | PHASE3 |
| NCT06239467 | OnKure, Inc. | Advanced Cancer|Breast Cancer|Advanced Solid Tumors|PI3K Gene Mutation | 2024-02-26 | PHASE1 |
| NCT03379428 | US Oncology Research|AbbVie|Pharmacyclics LLC. | Breast Neoplasms|Malignant Neoplasm of Breast | 2017-11-29 | PHASE1|PHASE2 |
| NCT00847171 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) | Breast Cancer | 2008-12 | PHASE2 |
| NCT02019277 | Hoffmann-La Roche | Breast Cancer | 2013-12-05 | PHASE3 |
| NCT06483386 | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 2024-07-15 | PHASE2 |
| NCT00194779 | University of Washington|National Cancer Institute (NCI) | Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2003-10 | PHASE2 |
| NCT03738553 | University of Washington | HER2-positive Breast Cancer | 2013-08 | |
| NCT01746771 | Hanmi Pharmaceutical Company Limited|National OncoVenture | HER-2 Positive Advanced Gastric Cancer | 2012-11 | PHASE1|PHASE2 |
| NCT07100600 | Henan Cancer Hospital | HER2-positive Advanced Breast Cancer|Brain Metastases|Radiotherapy | 2025-08-30 | PHASE2 |
| NCT00270894 | Accelerated Community Oncology Research Network|Aventis Pharmaceuticals | Breast Neoplasm | 2005-11 | PHASE2 |
| NCT06121700 | Fudan University | Adenocarcinoma|Stomach Neoplasm|Gastroesophageal-junction Cancer|Oligometastatic Disease|Metastatic Cancer|Metastatic Gastric Cancer|Adenocarcinoma of the Stomach|Gastroesophageal Junction Adenocarcinoma|Metastatic Adenocarcinoma | 2023-01-01 | PHASE2 |
| NCT00841828 | Spanish Breast Cancer Research Group|GlaxoSmithKline | Breast Cancer | 2009-02 | PHASE2 |
| NCT05218148 | Aiping Zhou | HER2-positive|Locally Advanced Solid Tumor|Immunotherapy|Sintilimab|S-1|Oxaliplatin|Gastric or Gastroesophageal Junction Adenocarcinoma | 2022-04-01 | PHASE2 |
| NCT01839500 | Hoffmann-La Roche | Gastric Cancer | 2013-04-25 | |
| NCT01817452 | West German Study Group|Roche Pharma AG | Breast Cancer | 2014-03 | PHASE2 |
| NCT02205047 | European Organisation for Research and Treatment of Cancer - EORTC | Malignant Neoplasm of Stomach|Malignant Neoplasm of Cardio-esophageal Junction of Stomach|Epidermal Growth Factor Receptor (EGFR) Protein Overexpression | 2015-07-15 | PHASE2 |
| NCT02627274 | Hoffmann-La Roche | Solid Tumor|Breast Cancer|Cancer of Head and Neck | 2015-12-07 | PHASE1 |
| NCT06409390 | H. Lee Moffitt Cancer Center and Research Institute | Metastatic Breast Cancer | 2024-08-14 | PHASE2 |
| NCT01273610 | City of Hope Medical Center|GlaxoSmithKline|Novartis | Breast Neoplasms|HER2+Neu Positive|Geriatric Health Services | 2011-04-20 | PHASE2 |
| NCT06100874 | Adrienne G. Waks|Gilead Sciences | Her 2 Positive Breast Cancer|Breast Cancer Female|Breast Cancer Metastatic | 2023-11-20 | PHASE2 |
| NCT01485926 | Cancer Trials Ireland | Breast Cancer | 2010-10 | PHASE2 |
| NCT06136897 | National Cancer Institute (NCI) | Malignant Solid Neoplasm | 2017-03-23 | PHASE2 |
| NCT01940497 | Hoffmann-La Roche | Breast Cancer | 2013-11-15 | PHASE3 |
| NCT03014076 | Cancer Insight, LLC | Breastcancer | 2008-01 | PHASE1 |
| NCT06145308 | Peking Union Medical College|Peking University Hospital of Stomatology | Salivary Gland Carcinoma|Precision Therapy | 2023-08-15 | PHASE2 |
| NCT02102438 | Instituto do Cancer do Estado de S?o Paulo | Breast Cancer|HER-2 Positive Breast Cancer | 2014-04 | NA |
| NCT06126640 | Jiangsu HengRui Medicine Co., Ltd. | HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | 2023-11-20 | PHASE3 |
| NCT01688609 | National Cancer Institute (NCI) | HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2012-07 | PHASE2 |
| NCT05755048 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 2023-03-28 | PHASE3 |
| NCT06819007 | Daiichi Sankyo | Ovarian Cancer | 2025-03-19 | PHASE3 |
| NCT00367471 | Novartis Pharmaceuticals | Neoplasms, Breast | 2006-12-07 | PHASE1 |
| NCT05081609 | Ascendis Pharma Oncology Division A+S | Advanced Solid Tumor|Locally Advanced Solid Tumor|Metastatic Solid Tumor|Platinum-resistant Ovarian Cancer|Post Anti-PD-1 Melanoma|2L&addition; Cervical Cancer|Neoadjuvant Melanoma|Neoadjuvant Non-Small Cell Lung Cancer|Post Anti-PD-(L)1 Non-Small Cell Lung Cancer|Post Anti-PD-(L)1 Small Cell Lung Cancer|Third Line or Later (3L&addition;) HER2&addition; Breast Cancer|Second or Third Line (2L+3L) Cervical Cancer|Third-line or Later (3L&addition;) Platinum-resistant Ovarian Cancer (PROC) | 2022-01-11 | PHASE1|PHASE2 |
| NCT04329065 | University of Washington|United States Department of Defense | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8 | 2022-04-20 | PHASE2 |
| NCT04042701 | Daiichi Sankyo|AstraZeneca|Merck Sharp & Dohme LLC | Breast Cancer|Non-small Cell Lung Carcinoma | 2020-02-10 | PHASE1 |
| NCT01427244 | Yale University|Genentech, Inc. | Paget´s Disease of the Vulva | 2011-08 | PHASE2 |
| NCT00826267 | Boehringer Ingelheim | Breast Neoplasms | 2009-01 | PHASE2 |
| NCT06730373 | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer|Metastatic Gastric Cancer|Unresectable Gastric Carcinoma | 2024-10-17 | PHASE2 |
| NCT03595592 | Fondazione Michelangelo|Hoffmann-La Roche | Invasive Breast Cancer | 2018-09-07 | PHASE3 |
| NCT01220128 | GlaxoSmithKline | Neoplasms, Breast | 2011-04-11 | PHASE2 |
| NCT04922008 | Fudan University | Breast Cancer | 2021-07-01 | PHASE2 |
| NCT06311214 | National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm | 2025-03-18 | PHASE2 |
| NCT05982678 | The Netherlands Cancer Institute|Daiichi Sankyo|AstraZeneca | HER2-positive Breast Cancer | 2024-05-02 | PHASE2 |
| NCT02896855 | Hoffmann-La Roche | Breast Cancer | 2016-09-13 | PHASE3 |
| NCT01301729 | Hoffmann-La Roche | Breast Cancer | 2011-03 | PHASE4 |
| NCT01228045 | National University Hospital, Singapore|National Cancer Centre, Singapore | Gastric Cancer | 2011-02 | PHASE2 |
| NCT00934856 | Hoffmann-La Roche | Breast Cancer | 2009-07 | PHASE1|PHASE2 |
| NCT02260531 | Dana-Farber Cancer Institute|Exelixis|Genentech, Inc. | Breast Cancer|Brain Tumor - Metastatic | 2014-11 | PHASE2 |
| NCT00971737 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) | Breast Cancer | 2009-07 | PHASE2 |
| NCT05659056 | The First Affiliated Hospital with Nanjing Medical University|Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 2022-11-29 | PHASE2 |
| NCT01472029 | AIO-Studien-gGmbH|Roche Pharma AG | Adenocarcinoma of the Gastroesophageal Junction|Adenocarcinoma of the Stomach | 2011-12 | PHASE2 |
| NCT00876395 | Novartis Pharmaceuticals | Breast Cancer | 2009-09-10 | PHASE3 |
| NCT07053085 | Memorial Sloan Kettering Cancer Center|Gateway for Cancer Research | Metastatic Breast Cancer|HER2-positive Breast Cancer | 2025-09-17 | PHASE2 |
| NCT07428044 | Memorial Sloan Kettering Cancer Center|AstraZeneca | Non-Small Cell Lung Cancer|Non-small Cell Lung Cancer Stage II|Non-Small Cell Lung Cancer Stage IIIA|Non-Small Cell Lung Cancer Stage IIIB | 2026-02-13 | PHASE2 |
| NCT00548184 | Baylor Breast Care Center|GlaxoSmithKline | Breast Cancer | 2008-05 | PHASE2 |
| NCT00251433 | Novartis Pharmaceuticals | Neoplasms, Breast | 2005-09-26 | PHASE1 |
| NCT07377643 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | HER2-positive Breast Cancer | 2026-02-10 | PHASE3 |
| NCT04960943 | Fudan University | Gastrointestinal Tumor|Effect of Drug | 2020-02-01 | PHASE2 |
| NCT05152147 | Jazz Pharmaceuticals|BeOne Medicines LTD|BeOne Pharmaceutical Co., Ltd. | Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma | 2021-12-02 | PHASE3 |
| NCT00256243 | Rita Sanghvi, Mehta | Breast Cancer | 2004-04 | PHASE2 |
| NCT01479179 | M.D. Anderson Cancer Center|Amgen | Breast Cancer | 2012-11 | PHASE1|PHASE2 |
| NCT01434303 | National Cancer Institute (NCI) | HER2+Neu Positive|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7 | 2012-01-10 | PHASE1 |
| NCT01077648 | GlaxoSmithKline | Cancer | 2010-02 | |
| NCT02100917 | Meiji Seika Pharma Co., Ltd.|Dong-A Pharmaceutical | Healthy Volunteer | 2014-01 | PHASE1 |
| NCT00085020 | Jonsson Comprehensive Cancer Center|GlaxoSmithKline | Breast Cancer | 2004-03 | PHASE1 |
| NCT07263425 | The First Affiliated Hospital with Nanjing Medical University|The Affiliated Brain Hospital of Nanjing Medical University | Leptomeningeal Metastasis of HER2-positive Breast Cancer | 2025-10-27 | PHASE2 |
| NCT00912340 | Emory University|Genentech, Inc.|Novartis Pharmaceuticals | Breast Cancer | 2009-05 | PHASE2 |
| NCT00637325 | Regione Lombardia|Mario Negri Institute for Pharmacological Research|Istituto Clinico Humanitas | Metastatic or Locally Advanced Breast Cancer | 2007-11 | PHASE3 |
| NCT00896376 | Centre Antoine Lacassagne | Breast Cancer | 2005-12 | NA |
| NCT05733689 | University of California, Irvine|BillionToOne Inc. | Gastroesophageal Adenocarcinoma | 2025-06-27 | PHASE1 |
| NCT07140393 | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 2025-10 | PHASE1|PHASE2 |
| NCT03179904 | Mayo Clinic | Advanced Breast Carcinoma|HER2-Positive Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|HER2-positive Breast Cancer | 2017-08-03 | PHASE2 |
| NCT00068341 | Jonsson Comprehensive Cancer Center|Aventis Pharmaceuticals|Genentech, Inc. | Breast Cancer | 2003-07 | PHASE2 |
| NCT00381901 | National Cancer Institute, France | Breast Cancer | 2006-05 | PHASE3 |
| NCT03498521 | Hoffmann-La Roche|Foundation Medicine | Cancer of Unknown Primary Site | 2018-07-10 | PHASE2 |
| NCT02536339 | Genentech, Inc. | Metastatic Breast Cancer | 2015-12-16 | PHASE2 |
| NCT00003995 | National Cancer Institute (NCI) | Colorectal Cancer | 1999-09 | PHASE2 |
| NCT05063786 | Spanish Breast Cancer Research Group|ETOP IBCSG Partners Foundation|Breast International Group|Novartis Pharmaceuticals | Advanced Breast Cancer | 2021-09-14 | PHASE3 |
| NCT00954512 | Merck Sharp & Dohme LLC | Neoplasms | 2009-09-25 | PHASE1|PHASE2 |
| NCT02213042 | Novartis Pharmaceuticals | Neoplasms, Breast | 2014-10-24 | PHASE2 |
| NCT05997524 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Advanced Gastric Carcinoma | 2021-03-01 | PHASE2 |
| NCT03863223 | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Breast Cancer | 2019-04-22 | PHASE3 |
| NCT06727227 | AstraZeneca | Breast Cancer | 2025-01-29 | |
| NCT02445586 | Hoffmann-La Roche | Breast Cancer | 2015-08-17 | PHASE4 |
| NCT07040059 | Aurigene Discovery Technologies Limited | HER 2 Positive Gastric Cancer|Gastroesophageal Junction Adenocarcinoma | 2025-03-22 | PHASE1|PHASE2 |
| NCT00006108 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 1999-08 | PHASE1|PHASE2 |
| NCT00003797 | Brown University|National Cancer Institute (NCI) | Pancreatic Cancer | 1999-03 | PHASE2 |
| NCT02725424 | Chinese Academy of Medical Sciences | Gastric Cancer | 2015-08 | PHASE2 |
| NCT01187381 | Hoffmann-La Roche | Breast Cancer | 2010-04-14 | |
| NCT06750484 | Yale University|Daiichi Sankyo|AstraZeneca | Breast Cancer Metastatic | 2025-06-20 | PHASE2 |
| NCT04585958 | National Cancer Institute (NCI) | Metastatic Malignant Solid Neoplasm|Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma|Unresectable Malignant Solid Neoplasm | 2021-05-21 | PHASE1 |
| NCT03747120 | University of Texas Southwestern Medical Center|Merck Sharp & Dohme LLC|Breast Cancer Research Foundation | HER2-positive Breast Cancer|Breast Cancer | 2019-01-25 | PHASE2 |
| NCT05786716 | Cancer Research UK|University of Manchester|University of Birmingham|Royal Marsden NHS Foundation Trust|Hoffmann-La Roche | Haematological Malignancy|Colorectal Neoplasms|Urinary Bladder Neoplasm|Gallbladder Neoplasms|Salivary Gland Neoplasm|Lung Neoplasm|Pancreatic Neoplasm|Ovarian Neoplasms|Prostatic Neoplasm|Skin Neoplasm|Solid Tumour | 2023-03-07 | PHASE2|PHASE3 |
| NCT00169104 | Dartmouth-Hitchcock Medical Center|Amgen | Metastatic Breast Cancer | 2002-07 | PHASE2|PHASE3 |
| NCT01205217 | GlaxoSmithKline | Neoplasms, Breast | 2010-12 | PHASE2 |
| NCT07315750 | RemeGen Co., Ltd. | Gastric Carcinoma | 2026-01-01 | PHASE3 |
| NCT00795678 | Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI) | Breast Cancer|Metastatic Cancer | 2008-09 | |
| NCT04425018 | Dana-Farber Cancer Institute|MacroGenics|Translational Breast Cancer Research Consortium | Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer | 2020-07-13 | PHASE2 |
| NCT07150208 | Fudan University | Breast Cancer With Brain Metastasis|HER2-low Expressing Breast Cancer | 2025-09 | PHASE2 |
| NCT01290718 | Hoffmann-La Roche | Breast Cancer | 2011-12 | PHASE2 |
| NCT00297596 | SCRI Development Innovations, LLC|Sanofi | Breast Cancer | 2006-02 | PHASE2 |
| NCT02731313 | Hoffmann-La Roche | Gastric Cancer, Gastroesophageal Junction Cancer | 2012-07 | |
| NCT04928261 | Ottawa Hospital Research Institute | Breast Cancer | 2021-12-13 | PHASE4 |
| NCT01705340 | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer | 2012-09 | PHASE1 |
| NCT00605397 | Memorial Sloan Kettering Cancer Center | Breast Cancer | 2007-01 | PHASE1 |
| NCT07086768 | Lei Zheng|Biosin USA, Inc. | Solid Tumor|Advanced Solid Tumor|Metastatic Solid Tumor | 2026-01-01 | PHASE1 |
| NCT04609540 | Shandong Cancer Hospital and Institute | HER2-positive Breast Cancer|Metastatic Breast Cancer | 2021-01-01 | |
| NCT04102618 | Oncolytics Biotech|SOLTI Breast Cancer Research Group | Breast Cancer | 2019-03-29 | EARLY_PHASE1 |
| NCT07454668 | Baptist Health South Florida|National Brain Tumor Society | Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Cancer|Cancer Metastatic | 2026-06 | PHASE1 |
| NCT07003074 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 2025-06-23 | PHASE3 |
| NCT07102381 | Jazz Pharmaceuticals|Jazz Pharmaceuticals Ireland Limited | HER2-positive Breast Cancer|Breast Cancer | 2025-09-24 | PHASE2 |
| NCT04588545 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. | HER2-positive Breast Cancer|Leptomeningeal Metastasis|Leptomeningeal Disease | 2020-12-10 | PHASE1|PHASE2 |
| NCT02568839 | Thomas Hatschek | Early-Stage Breast Carcinoma|HER-2 Positive Breast Cancer | 2014-11 | PHASE2|PHASE3 |
| NCT02656589 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Huiping Li,M.D., Ph.D.,Peking University Cancer Hospital | Breast Cancer | 2015-06 | |
| NCT02901301 | Yonsei University | Gastric Cancer | 2017-02-06 | PHASE1|PHASE2 |
| NCT07022483 | Daiichi Sankyo|AstraZeneca | Endometrial Cancer | 2025-09-30 | PHASE3 |
| NCT05420454 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 2022-07-10 | PHASE4 |
| NCT05704829 | West German Study Group|AstraZeneca | HER2-positive Early Breast Cancer | 2024-02-05 | PHASE2 |
| NCT04589845 | Hoffmann-La Roche | Solid Tumors | 2021-01-18 | PHASE2 |
| NCT00458237 | Beth Israel Deaconess Medical Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute | Breast Cancer | 2007-04 | PHASE1|PHASE2 |
| NCT00151034 | University of Michigan Rogel Cancer Center|Genentech, Inc. | Urologic Neoplasms | 2000-09 | PHASE2 |
| NCT00795899 | GBG Forschungs GmbH|AGO Study Group | Breast Cancer | 2002-01 | PHASE2 |
| NCT05189067 | Second Affiliated Hospital, School of Medicine, Zhejiang University | HER2-positive Breast Cancer|Adjuvant Therapy | 2022-01-31 | PHASE2|PHASE3 |
| NCT02827877 | City of Hope Medical Center|National Cancer Institute (NCI) | HER2 Positive Breast Carcinoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2016-07-15 | PHASE2 |
| NCT00829166 | Hoffmann-La Roche | Breast Cancer | 2009-02 | PHASE3 |
| NCT02154529 | Kadmon Corporation, LLC | HER-2 Positive Breast Cancer|Metastatic Malignant Neoplasm to Brain | 2014-05 | PHASE1|PHASE2 |
| NCT02091141 | Genentech, Inc. | Neoplasms|Solid Tumors|Biliary Cancer|Salivary Cancer|Bladder Cancer | 2014-04-14 | PHASE2 |
| NCT05253651 | Seagen, a wholly owned subsidiary of Pfizer | Colorectal Neoplasms | 2022-10-24 | PHASE3 |
| NCT04082364 | MacroGenics|Zai Lab (Shanghai) Co., Ltd. | Gastric Cancer|Gastroesophageal Junction Cancer|HER2-positive Gastric Cancer | 2019-09-30 | PHASE2|PHASE3 |
| NCT02472964 | Mylan Inc.|Mylan GmbH | Breast Cancer | 2012-07 | PHASE3 |
| NCT02132949 | Hoffmann-La Roche | Breast Cancer | 2014-07-14 | PHASE2 |
| NCT03153163 | Hoffmann-La Roche | Breast Neoplasms | 2017-06-20 | PHASE1 |
| NCT03756064 | Zhejiang Cancer Hospital | Breast Cancer|Neoplasm, Breast|Breast Diseases | 2019-08-01 | NA |
| NCT01454804 | M.D. Anderson Cancer Center | Advanced Cancers | 2011-10 | PHASE1 |
| NCT04197687 | Academic and Community Cancer Research United|National Cancer Institute (NCI) | Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2020-02-20 | PHASE2 |
| NCT01785420 | Dr Rajendra A. Badwe|Tata Memorial Hospital | Carcinoma Breast Stage I|HER2 Positive Breast Cancer | 2013-05 | PHASE3 |
| NCT00006089 | National Cancer Institute (NCI)|Gynecologic Oncology Group | Endometrial Adenocarcinoma|ERBB2 Gene Amplification|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7 | 2000-09-18 | PHASE2 |
| NCT02907918 | Washington University School of Medicine|Pfizer|Rising Tide Foundation | Breast Cancer|Cancer of Breast|Breast Carcinoma | 2017-06-30 | PHASE2 |
| NCT07116824 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 2025-09-15 | PHASE2 |
| NCT00968682 | Cancer Trials Ireland | Breast Cancer|Cardiac Toxicity | 2008-04 | |
| NCT02073487 | The Methodist Hospital Research Institute|Celgene Corporation|Novartis | Breast Cancer | 2014-02 | PHASE2 |
| NCT05760612 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Early-stage Breast Cancer|HER2-positive Breast Cancer|Adjuvant Treatment After Trastuzumab|RCB Classification 1-2|Neratini | 2023-03-14 | PHASE3 |
| NCT00003612 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Breast Cancer | 1999-04 | PHASE2 |
| NCT04175171 | Genor Biopharma Co., Ltd. | Metastatic Breast Cancer | 2011-11-07 | PHASE1 |
| NCT07335081 | Shanghai Jiao Tong University School of Medicine | Breast Cancer | 2024-02-01 | PHASE2 |
| NCT04888663 | Yonsei University | Recurrent+Metastatic Gastric Cancer | 2018-02-13 | PHASE1|PHASE2 |
| NCT03006172 | Genentech, Inc. | Breast Cancer|Solid Tumor | 2016-12-13 | PHASE1 |
| NCT01106898 | University of Nebraska|National Cancer Institute (NCI) | Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer | 2010-03-24 | PHASE2 |
| NCT00811993 | Hoffmann-La Roche | Neoplasms | 2009-02 | PHASE1 |
| NCT04547907 | Henan Cancer Hospital | Breast Cancer,HER2-positive | 2020-09-18 | PHASE3 |
| NCT01597414 | European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche | Elderly Metastatic Breast Cancer Population | 2013-06 | PHASE2 |
| NCT01702558 | Hoffmann-La Roche | Breast Cancer|Gastric Cancer | 2012-12-03 | PHASE2 |
| NCT05900206 | Karolinska University Hospital | Breast Cancer | 2023-10-26 | PHASE2 |
| NCT00005635 | Genentech, Inc.|National Cancer Institute (NCI) | Breast Cancer | 2000-01 | PHASE2 |
| NCT00088985 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation | Breast Cancer | 2004-01 | PHASE2 |
| NCT01921335 | Dana-Farber Cancer Institute|Array BioPharma|Breast Cancer Research Foundation | Brain Metastases From HER2 and Breast Cancer|Advanced HER2-positive Breast Cancer | 2013-08 | PHASE1 |
| NCT06328738 | Enliven Therapeutics | HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2 Positive Solid Tumors|HER2 Amplification|Colorectal Cancer | 2024-05-30 | PHASE1 |
| NCT01679743 | National Cancer Institute (NCI) | Breast Cancer|Lung Neoplasms|Breast Neoplasms|Lung Cancer | 2012-08-29 | PHASE2 |
| NCT01730833 | City of Hope Medical Center|National Cancer Institute (NCI) | HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Breast Adenocarcinoma|Inflammatory Breast Carcinoma | 2013-07-17 | PHASE2 |
| NCT06210776 | Daiichi Sankyo | HER2-positive Breast Cancer|HER2-low Breast Cancer|Breast Cancer|Advanced Cancer | 2024-01-15 | |
| NCT01745965 | West German Study Group|Roche Pharma AG | Breast Cancer | 2012-11 | PHASE2 |
| NCT01041404 | Hoffmann-La Roche|Chugai Pharmaceutical | Gastric Cancer | 2005-09 | PHASE3 |
| NCT07386938 | R-Pharm | Locally Advanced Breast Cancer|Metastatic Breast Cancer | 2024-08-09 | PHASE3 |
| NCT06843681 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Peking University Shenzhen Hospital | Breast Carcinoma in Situ | 2025-03-01 | PHASE2 |
| NCT02297698 | Cancer Insight, LLC|Genentech, Inc.|Sellas Life Sciences Group | Breast Cancer | 2014-10 | PHASE2 |
| NCT00450892 | European Organisation for Research and Treatment of Cancer - EORTC|GlaxoSmithKline | Breast Cancer | 2007-02 | PHASE1|PHASE2 |
| NCT05378464 | H. Lee Moffitt Cancer Center and Research Institute|Vaccinex Inc. | HER2-positive Breast Cancer | 2022-05-31 | PHASE1 |
| NCT00875238 | Vanderbilt University|National Cancer Institute (NCI) | Breast Cancer|Cardiac Toxicity|Cardiovascular Complications | 2008-06 | |
| NCT03556358 | Tanvex BioPharma USA, Inc. | Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2018-06-28 | PHASE3 |
| NCT04539938 | Seagen, a wholly owned subsidiary of Pfizer | HER2 Positive Breast Cancer | 2020-12-01 | PHASE2 |
| NCT00976989 | Hoffmann-La Roche | Breast Cancer | 2009-11 | PHASE2 |
| NCT03013218 | ALX Oncology Inc. | Metastatic Cancer|Solid Tumor|Advanced Cancer|NonHodgkin Lymphoma | 2017-02-03 | PHASE1 |
| NCT07152782 | Fudan University | Breast Cancer With Brain Metastasis|HER2-positive Breast Cancer | 2025-11 | PHASE2 |
| NCT06250777 | Yonsei University | Non Small Cell Lung Cancer | 2024-07-11 | PHASE2 |
| NCT02318901 | Western Regional Medical Center | Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer | 2014-10 | PHASE1|PHASE2 |
| NCT01160211 | Novartis Pharmaceuticals|GlaxoSmithKline | Neoplasms, Breast | 2011-05-05 | PHASE3 |
| NCT02125344 | GBG Forschungs GmbH|Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma | Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer | 2014-12 | PHASE3 |
| NCT00398437 | Jules Bordet Institute | Breast Cancer|Metastatic Cancer | 2006-09 | NA |
| NCT06625775 | TheRas, Inc., d+b+a BBOT (BridgeBio Oncology Therapeutics) | Solid Tumor, Adult|Metastatic Breast Cancer|Advanced Breast Cancer|HER2 Mutation-Related Tumors|HER2-positive Metastatic Breast Cancer|KRAS Mutant Metastatic Colorectal Cancer|Metastatic Lung Cancer|Metastatic Colorectal Cancer|Advanced Lung Cancer|HR-positive, HER2-negative Advanced Breast Cancer|HER2-positive Advanced Breast Cancer | 2024-10-29 | PHASE1 |
| NCT00788931 | Novartis Pharmaceuticals | HER-2 Positive Breast Cancer|Metastatic Breast Cancer | 2008-12 | PHASE1 |
| NCT05715931 | Yu jiren | Adenocarcinoma of the Stomach|Adenocarcinoma of Esophagogastric Junction|HER2-positive Gastric Cancer | 2023-02-28 | PHASE2 |
| NCT02060253 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Synta Pharmaceuticals Corp.|New York University Cancer Institute | HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2014-04 | PHASE1 |
| NCT00434031 | National Cancer Institute, Naples | Breast Cancer | 2007-09 | PHASE2 |
| NCT06123338 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Merck Sharp & Dohme LLC | Esophageal Cancer|Gastric Adenocarcinoma|HER2 Gene Mutation | 2024-02-01 | PHASE2 |
| NCT01736410 | National Cancer Centre, Singapore | HER 2 Positive Advanced Gastric Cancer | 2010-05 | PHASE2 |
| NCT00004013 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 1999-01 | PHASE2 |
| NCT00016276 | National Cancer Institute (NCI) | Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer | 2001-05 | PHASE3 |
| NCT03334617 | AstraZeneca | Non-Small Cell Lung Cancer | 2017-12-18 | PHASE2 |
| NCT02003209 | National Cancer Institute (NCI)|NRG Oncology | HER2-Positive Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2014-02-18 | PHASE3 |
| NCT05985187 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HER2-positive Breast Cancer | 2020-10-20 | PHASE3 |
| NCT04420598 | MedSIR|Daiichi Sankyo | Advanced Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Leptomeningeal Metastasis | 2020-05-25 | PHASE2 |
| NCT00004163 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Genentech, Inc. | Head and Neck Cancer | 1999-10 | PHASE2 |
| NCT00309556 | Austrian Breast & Colorectal Cancer Study Group|Amgen|Ebewe Pharma GmbH|Hoffmann-La Roche|Sanofi | Breast Cancer | 2005-02 | PHASE3 |
| NCT03735966 | Henan Cancer Hospital | HER2 Positive Breast Cancer | 2018-11-20 | PHASE2 |
| NCT04579380 | Seagen, a wholly owned subsidiary of Pfizer | Uterine Neoplasms|Uterine Cervical Neoplasms|Biliary Tract Neoplasms|Urologic Neoplasms|Carcinoma, Non-Small-Cell Lung|HER2 Mutations Breast Neoplasms | 2021-01-11 | PHASE2 |
| NCT00431704 | National Cancer Institute, Naples | Metastatic Breast Cancer | 2007-10 | PHASE2 |
| NCT00944047 | University of Kansas Medical Center|Celgene Corporation | Breast Cancer | 2009-07 | PHASE2 |
| NCT00923299 | Institut du Cancer de Montpellier - Val d´Aurelle | Pancreatic Cancer | 2008-12 | PHASE1|PHASE2 |
| NCT05945732 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer|Metastatic Breast Cancer|HER2-low Expressing Breast Cancer | 2023-10-24 | |
| NCT06190600 | The Greater Poland Cancer Centre | Breast Cancer | 2018-10-11 | NA |
| NCT02488564 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | HER-2 Positive Breast Cancer | 2014-12-17 | PHASE2 |
| NCT07543536 | Sun Yat-sen University | Advanced+Metastatic Breast Cancer|HER2&addition;, Low, or Ultralow Advanced+Metastatic Breast Cancer | 2026-05-01 | PHASE3 |
| NCT05458401 | Daiichi Sankyo | HER2-positive Breast Cancer | 2022-11-11 | |
| NCT00019812 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) | Breast Cancer | 1999-08 | PHASE2 |
| NCT07416253 | Henan Cancer Hospital | Breast Cancer | 2026-03 | PHASE2 |
| NCT01387295 | Dorte Nielsen | Metastatic Breast Cancer|Liver Metastases | 2010-04 | PHASE2 |
| NCT01875367 | Spanish Breast Cancer Research Group | Breast Cancer | 2013-09-18 | PHASE3 |
| NCT03199300 | University Medical Center Groningen | Toxicity Due to Chemotherapy|Cardiovascular Morbidity|Cancer, Treatment-Related | 2017-12-12 | |
| NCT06771622 | FBD Biologics Limited | Solid Cancer | 2025-03-13 | PHASE1|PHASE2 |
| NCT01764022 | Biocad | Human Epithelial Receptor (HER)-2 Positive Breast Cancer | 2012-10 | PHASE3 |
| NCT02320435 | Hoffmann-La Roche | Solid Tumors | 2015-02-02 | PHASE3 |
| NCT03613168 | Changhoon Yoo | Cholangiocarcinoma|Biliary Tract Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification | 2019-06-01 | PHASE2 |
| NCT00593697 | Finnish Breast Cancer Group | Breast Neoplasms | 2008-01 | PHASE3 |
| NCT00266110 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation | Breast Cancer | 2005-12 | PHASE2 |
| NCT00401427 | National Cancer Institute, Naples | Metastatic Breast Cancer | 2002-11 | PHASE2 |
| NCT00084513 | Fox Chase Cancer Center|National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 2004-08 | PHASE1 |
| NCT06973525 | Hebei Medical University Fourth Hospital | HER2-positive Breast Cancer | 2025-09-01 | PHASE2 |
| NCT04538742 | AstraZeneca|Daiichi Sankyo Company, Limited | Metastatic Breast Cancer | 2020-12-28 | PHASE1|PHASE2 |
| NCT07366840 | Fudan University | HER2-positive Breast Cancer|Metastatic Breast Cancer | 2026-01-16 | PHASE2|PHASE3 |
| NCT04740918 | Hoffmann-La Roche | Metastatic Breast Cancer | 2021-06-07 | PHASE3 |
| NCT01295086 | Odense University Hospital|Aalborg University Hospital|Aarhus University Hospital|Rigshospitalet, Denmark | Adenocarcinoma | 2011-03 | NA |
| NCT03947242 | Henan Cancer Hospital | HER2 Positive Breast Cancer | 2019-06-01 | NA |
| NCT03845270 | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage III|HER2 Gene Mutation | 2019-05-17 | PHASE2 |
| NCT00005831 | National Cancer Institute (NCI) | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Squamous Cell Carcinoma of the Bladder|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder | 2000-03 | PHASE2 |
| NCT00567879 | Novartis Pharmaceuticals | Breast Cancer | 2008-04 | PHASE1|PHASE2 |
| NCT01125566 | Boehringer Ingelheim | Breast Neoplasms | 2010-06-22 | PHASE3 |
| NCT04499924 | Seagen Inc. | Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma | 2021-03-22 | PHASE2|PHASE3 |
| NCT07214766 | Genentech, Inc. | Healthy Participants | 2025-10-17 | PHASE1 |
| NCT01042379 | QuantumLeap Healthcare Collaborative | Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2010-03-01 | PHASE2 |
| NCT00250874 | Zeneus Pharma | Metastatic Breast Cancer | 2003-12 | PHASE2 |
| NCT04367090 | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Breast Cancer | 2020-05-28 | PHASE1 |
| NCT04049409 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Healthy Volunteers | 2019-06-17 | PHASE1 |
| NCT06595563 | Jules Bordet Institute|Hoffmann-La Roche | HER2-positive Metastatic Breast Cancer|HER2-positive Advanced Breast Cancer | 2026-06-30 | PHASE2 |
| NCT01471847 | Novartis Pharmaceuticals | Locally Advance Breast Cancer (LABC)|Metastatic Breast Cancer (MBC) | 2012-02 | PHASE1 |
| NCT02289833 | Hoffmann-La Roche | Non-Small Cell Lung Cancer | 2014-12-15 | PHASE2 |
| NCT02229149 | US Oncology Research|Genentech, Inc. | Breast Neoplasms|Malignant Tumor of the Breast | 2014-12 | PHASE2 |
| NCT06551220 | Sun Yat-sen University | Metastatic Breast Cancer | 2022-10-10 | |
| NCT05838066 | Shanghai JMT-Bio Inc. | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | 2023-07-23 | PHASE3 |
| NCT05408845 | NRG Oncology|National Cancer Institute (NCI) | Metastatic Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage III Major Salivary Gland Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Unresectable Salivary Gland Carcinoma | 2023-03-03 | PHASE2 |
| NCT01959490 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2013-09-24 | PHASE2 |
| NCT01191697 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Genentech, Inc. | Esophageal Cancer|Gastric Cancer | 2011-02 | PHASE2 |
| NCT02909751 | Vejle Hospital | Breast Cancer | 2016-09-14 | PHASE2 |
| NCT05710666 | Cancer Trials Ireland | HER2-positive Breast Cancer | 2023-10-26 | PHASE2 |
| NCT00009997 | NYU Langone Health|National Cancer Institute (NCI) | Breast Cancer | 1999-03 | PHASE1 |
| NCT07136974 | Henan Cancer Hospital | Breast Cancer|HER2 &addition; Breast Cancer | 2025-09-01 | PHASE2 |
| NCT05577923 | Fudan University | Metastatic Breast Cancer | 2022-11-01 | PHASE2 |
| NCT06178445 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel|MSD Sharp & Dohme GmbH, Germany | Biliary Tract Cancer|HER2 Gene Mutation|HER2 | 2024-04-17 | PHASE2 |
| NCT01384253 | Orano Med LLC | Breast Neoplasms|Peritoneal Neoplasms|Ovarian Neoplasms|Pancreatic Neoplasms|Stomach Neoplasms | 2011-07 | PHASE1 |
| NCT01367002 | Yale University|Genentech, Inc. | Endometrial Cancer | 2011-06 | PHASE2 |
| NCT06846437 | Shanghai JMT-Bio Inc. | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | 2025-02-18 | PHASE3 |
| NCT06510465 | RenJi Hospital | Breast Cancer | 2024-08-01 | PHASE2 |
| NCT04760431 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Peking University International Hospital|Sun Yat-sen University|Zhejiang University | HER2-positive Breast Cancer|Brain Metastases | 2021-10-01 | PHASE2 |
| NCT00193063 | SCRI Development Innovations, LLC|Eli Lilly and Company|Genentech, Inc. | Breast Cancer | 2001-07 | PHASE2 |
| NCT05983094 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Chinese Academy of Medical Sciences|Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center|First Hospital of China Medical University | Breast Cancer|Neoadjuvant Therapy | 2023-09-01 | PHASE2 |
| NCT04024462 | Hoffmann-La Roche | HER2-positive Early Breast Cancer | 2020-02-05 | PHASE3 |
| NCT00943670 | Genentech, Inc. | Metastatic Breast Cancer | 2009-07 | PHASE2 |
| NCT00006015 | National Cancer Institute (NCI) | Colorectal Cancer | 2000-05 | PHASE2 |
| NCT05020860 | Baylor Breast Care Center | Breast Cancer|Breast Neoplasm|Breast Cancer Female|Breast Cancer Invasive|Breast Cancer Stage II|Breast Cancer Stage III|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Neoplasms|Estrogen Receptor-positive Breast Cancer | 2023-04-18 | PHASE2 |
| NCT02705859 | Cancer Trials Ireland | HER2 Positive Breast Cancer | 2016-04 | PHASE1 |
| NCT02465060 | National Cancer Institute (NCI) | Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Exocrine Pancreas Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Kidney Carcinoma|Liver Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Corpus Neoplasm|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Uterine Corpus Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma | 2015-08-17 | PHASE2 |
| NCT01973660 | SOLTI Breast Cancer Research Group|Novartis | Breast Cancer | 2013-10 | PHASE2 |
| NCT00242203 | Washington University School of Medicine|Novartis|Pfizer | Breast Neoplasms | 2002-10 | PHASE2 |
| NCT01897441 | Albert Einstein College of Medicine|National Cancer Institute (NCI) | Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2013-06 | NA |
| NCT06731803 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Daiichi Sankyo | Esophagogastric Adenocarcinoma | 2025-03-25 | PHASE1|PHASE2 |
| NCT01026142 | Hoffmann-La Roche | Breast Cancer | 2010-01-26 | PHASE3 |
| NCT05426486 | Caigang Liu | HER2-positive Breast Cancer | 2022-05-23 | PHASE2|PHASE3 |
| NCT01748773 | Hoffmann-La Roche | Gastric Cancer|Gastroesophageal Junction Cancer | 2013-01-29 | PHASE2 |
| NCT06686394 | Merck Sharp & Dohme LLC|Daiichi Sankyo | Breast Neoplasms|Breast Cancer | 2025-02-26 | PHASE1|PHASE2 |
| NCT01271920 | Novartis Pharmaceuticals | Advanced HER2-positive Breast Cancer | 2010-09 | PHASE1|PHASE2 |
| NCT00927589 | Genentech, Inc. | Solid Cancers | 2009-07 | PHASE1 |
| NCT06217185 | Hebei Medical University Fourth Hospital | HER2-positive Breast Cancer|Advanced Breast Cancer | 2024-01-02 | PHASE4 |
| NCT02040935 | Hoffmann-La Roche | Breast Cancer | 2014-02-21 | PHASE3 |
| NCT03811418 | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen | Advanced Breast Cancer|HER2-positive Breast Cancer | 2019-01 | PHASE3 |
| NCT04430738 | Seagen, a wholly owned subsidiary of Pfizer | Colorectal Carcinoma|Gastric Adenocarcinoma|GEJ Adenocarcinoma|Esophageal Adenocarcinoma|Cholangiocarcinoma|Gallbladder Carcinoma | 2020-09-15 | PHASE2 |
| NCT07441460 | Shanghai JMT-Bio Inc. | Resectable HER2-positive Breast Cancer | 2026-03-06 | PHASE3 |
| NCT00258349 | National Cancer Institute (NCI) | Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2006-08 | PHASE1|PHASE2 |
| NCT04704661 | National Cancer Institute (NCI) | Advanced Breast Carcinoma|Advanced Colon Carcinoma|Advanced Colorectal Carcinoma|Advanced Endometrial Carcinoma|Advanced Gastric Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Salivary Gland Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|HER2-Positive Breast Carcinoma|Malignant Hepatobiliary Neoplasm|Metastatic Breast Carcinoma|Metastatic Colon Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Endometrial Carcinoma|Metastatic Gastric Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Salivary Gland Carcinoma|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Major Salivary Gland Cancer AJCC v8|Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Unresectable Breast Carcinoma|Unresectable Colon Carcinoma|Unresectable Colorectal Carcinoma|Unresectable Endometrial Carcinoma|Unresectable Gastric Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Salivary Gland Carcinoma | 2021-08-09 | PHASE1 |
| NCT07459673 | Memorial Sloan Kettering Cancer Center | Breast Cancer|HER2-positive Breast Cancer|Breast Cancer Stage IV | 2026-03-04 | PHASE2 |
| NCT06172127 | MedSIR|Hoffmann-La Roche | HER2-positive Breast Cancer | 2024-07-22 | PHASE2 |
| NCT07151586 | UNICANCER | Triple Negative Breast Neoplasms|Neoplasm Metastasis|HER 2 Low-expressing Breast Cancer | 2025-10 | PHASE2 |
| NCT00033514 | Jonsson Comprehensive Cancer Center|Genentech, Inc. | Breast Cancer | 2001-08 | PHASE1|PHASE2 |
| NCT04512261 | Reva Basho|Merck Sharp & Dohme LLC|Seagen Inc. | Breast Cancer|Brain Metastases|HER2-positive Breast Cancer|CNS Disease | 2022-06-01 | PHASE1|PHASE2 |
| NCT06907082 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Breast Cancer | 2020-12-28 | NA |
| NCT00960960 | Genentech, Inc. | Breast Cancer | 2009-08 | PHASE1 |
| NCT07196774 | Jiangsu HengRui Medicine Co., Ltd. | Early-stage or Locally Advanced HER2-positive Breast Cancer | 2025-10-23 | PHASE3 |
| NCT04908813 | Shanghai Henlius Biotech | Gastric Cancer | 2021-09-29 | PHASE2 |
| NCT01401959 | SCRI Development Innovations, LLC|Eisai Inc. | Metastatic Breast Cancer | 2011-09-23 | PHASE2 |
| NCT02682693 | GBG Forschungs GmbH|Amgen|Celgene Corporation | Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III | 2017-02-13 | PHASE2 |
| NCT06057610 | Jiangsu HengRui Medicine Co., Ltd. | HER2-PositiveRecurrent or Metastatic Breast Cancer | 2023-10-16 | PHASE3 |
| NCT00533936 | Instituto Nacional de Cancerologia, Columbia | Breast Cancer | 2006-09 | PHASE2 |
| NCT07059338 | Sun Yat-sen University | HER2 Positive|Colorectal Cancer (CRC) | 2025-07-11 | PHASE2 |
| NCT00148876 | GBG Forschungs GmbH|Hoffmann-La Roche | Breast Cancer | 2003-09 | PHASE3 |
| NCT06525298 | Eisbach Bio GmbH | Advanced Solid Tumor|Homologous Recombination Deficiency|HRR Deficiency | 2024-09-09 | PHASE1|PHASE2 |
| NCT01985893 | Berufsverband Niedergelassener Gyn?kologischer Onkologen in Deutschland e.V.|OnkoDataMed GmbH | Metastatic Breast Cancer | 2013-09 | PHASE2 |
| NCT03418558 | Fondazione del Piemonte per l´Oncologia | Metastatic Colorectal Cancer | 2015-07-08 | PHASE2 |
| NCT04307329 | The Netherlands Cancer Institute|AstraZeneca | Breast Cancer | 2021-03-23 | PHASE2 |
| NCT07126561 | University of Chicago | HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2 | 2026-11-01 | PHASE2 |
| NCT00769379 | National Cancer Institute (NCI)|NRG Oncology | Breast Ductal Carcinoma In Situ | 2008-12-10 | PHASE3 |
| NCT05722886 | Cancer Research UK|University of Manchester|University of Birmingham|Royal Marsden NHS Foundation Trust|Hoffmann-La Roche|Novartis Pharmaceuticals | Haematological Malignancy|Solid Tumour | 2023-03-01 | PHASE2|PHASE3 |
| NCT00509769 | Genentech, Inc. | Metastatic Breast Cancer | 2007-07 | PHASE2 |
| NCT03820141 | The Methodist Hospital Research Institute|AstraZeneca | Breast Cancer | 2020-06-30 | PHASE2 |
| NCT06764875 | AstraZeneca | HER2-positive Gastric Cancer|Gastroesophageal Junction Adenocarcinoma | 2025-03-01 | PHASE3 |
| NCT01204372 | Institut du Cancer de Montpellier - Val d´Aurelle | Metastatic Pancreatic Adenocarcinoma | 2010-06 | PHASE2 |